nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—CSK—systemic scleroderma	0.389	0.685	CbGaD
Dasatinib—BLK—systemic scleroderma	0.179	0.315	CbGaD
Dasatinib—ABCG2—Leflunomide—systemic scleroderma	0.0263	0.225	CbGbCtD
Dasatinib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0162	0.139	CbGbCtD
Dasatinib—CYP1A2—Pentoxifylline—systemic scleroderma	0.0114	0.0973	CbGbCtD
Dasatinib—CYP1A2—Leflunomide—systemic scleroderma	0.0108	0.0928	CbGbCtD
Dasatinib—ABCB1—Lisinopril—systemic scleroderma	0.00994	0.0851	CbGbCtD
Dasatinib—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.009	0.077	CbGbCtD
Dasatinib—ABCB1—Captopril—systemic scleroderma	0.00744	0.0637	CbGbCtD
Dasatinib—ABCG2—Methotrexate—systemic scleroderma	0.00652	0.0558	CbGbCtD
Dasatinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00586	0.0501	CbGbCtD
Dasatinib—ABCB1—Prednisone—systemic scleroderma	0.00468	0.0401	CbGbCtD
Dasatinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00351	0.03	CbGbCtD
Dasatinib—CYP3A4—Prednisone—systemic scleroderma	0.00281	0.024	CbGbCtD
Dasatinib—EPHA2—pulmonary artery—systemic scleroderma	0.00271	0.0377	CbGeAlD
Dasatinib—KIT—myenteric nerve plexus—systemic scleroderma	0.0027	0.0376	CbGeAlD
Dasatinib—ABCB1—Methotrexate—systemic scleroderma	0.00235	0.0201	CbGbCtD
Dasatinib—TESK1—Enalapril—Captopril—systemic scleroderma	0.00108	0.379	CbGdCrCtD
Dasatinib—RIPK2—endothelium—systemic scleroderma	0.00102	0.0142	CbGeAlD
Dasatinib—RIPK2—blood vessel—systemic scleroderma	0.000943	0.0131	CbGeAlD
Dasatinib—SIK2—connective tissue—systemic scleroderma	0.000913	0.0127	CbGeAlD
Dasatinib—TEC—tendon—systemic scleroderma	0.000906	0.0126	CbGeAlD
Dasatinib—SRC—artery—systemic scleroderma	0.00087	0.0121	CbGeAlD
Dasatinib—EPHB4—endothelium—systemic scleroderma	0.000864	0.012	CbGeAlD
Dasatinib—MAPK14—blood vessel—systemic scleroderma	0.000841	0.0117	CbGeAlD
Dasatinib—SRMS—connective tissue—systemic scleroderma	0.000831	0.0116	CbGeAlD
Dasatinib—EPHB4—blood vessel—systemic scleroderma	0.000797	0.0111	CbGeAlD
Dasatinib—JAK2—blood vessel—systemic scleroderma	0.000791	0.011	CbGeAlD
Dasatinib—BMX—skin of body—systemic scleroderma	0.000784	0.0109	CbGeAlD
Dasatinib—EPHA2—blood vessel—systemic scleroderma	0.000782	0.0109	CbGeAlD
Dasatinib—STAT5B—connective tissue—systemic scleroderma	0.00077	0.0107	CbGeAlD
Dasatinib—CSK—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.000746	0.262	CbGdCrCtD
Dasatinib—PTK6—skin of body—systemic scleroderma	0.000735	0.0102	CbGeAlD
Dasatinib—SRC—endothelium—systemic scleroderma	0.000735	0.0102	CbGeAlD
Dasatinib—EPHB1—tendon—systemic scleroderma	0.000711	0.00989	CbGeAlD
Dasatinib—STAT5B—skin of body—systemic scleroderma	0.000695	0.00968	CbGeAlD
Dasatinib—SRC—blood vessel—systemic scleroderma	0.000678	0.00943	CbGeAlD
Dasatinib—LYN—connective tissue—systemic scleroderma	0.000626	0.00872	CbGeAlD
Dasatinib—BTK—connective tissue—systemic scleroderma	0.000614	0.00854	CbGeAlD
Dasatinib—EPHB2—digestive system—systemic scleroderma	0.000613	0.00854	CbGeAlD
Dasatinib—SRMS—digestive system—systemic scleroderma	0.0006	0.00835	CbGeAlD
Dasatinib—KIT—endothelium—systemic scleroderma	0.000599	0.00834	CbGeAlD
Dasatinib—PTK6—digestive system—systemic scleroderma	0.000588	0.00818	CbGeAlD
Dasatinib—TESK1—connective tissue—systemic scleroderma	0.000569	0.00792	CbGeAlD
Dasatinib—STAT5B—digestive system—systemic scleroderma	0.000556	0.00774	CbGeAlD
Dasatinib—KIT—blood vessel—systemic scleroderma	0.000552	0.00769	CbGeAlD
Dasatinib—PDGFRB—blood vessel—systemic scleroderma	0.00054	0.00751	CbGeAlD
Dasatinib—BMX—lung—systemic scleroderma	0.000524	0.00729	CbGeAlD
Dasatinib—CSK—connective tissue—systemic scleroderma	0.000521	0.00725	CbGeAlD
Dasatinib—SRMS—lung—systemic scleroderma	0.000501	0.00698	CbGeAlD
Dasatinib—TXK—lung—systemic scleroderma	0.000496	0.0069	CbGeAlD
Dasatinib—PTK6—lung—systemic scleroderma	0.000491	0.00684	CbGeAlD
Dasatinib—RIPK2—connective tissue—systemic scleroderma	0.000484	0.00673	CbGeAlD
Dasatinib—CSK—smooth muscle tissue—systemic scleroderma	0.000477	0.00664	CbGeAlD
Dasatinib—SIK3—tendon—systemic scleroderma	0.000476	0.00662	CbGeAlD
Dasatinib—STK35—skin of body—systemic scleroderma	0.000474	0.00659	CbGeAlD
Dasatinib—SIK1—connective tissue—systemic scleroderma	0.000472	0.00657	CbGeAlD
Dasatinib—CSK—skin of body—systemic scleroderma	0.00047	0.00655	CbGeAlD
Dasatinib—ZAK—digestive system—systemic scleroderma	0.000465	0.00647	CbGeAlD
Dasatinib—STAT5B—lung—systemic scleroderma	0.000464	0.00646	CbGeAlD
Dasatinib—ERBB3—connective tissue—systemic scleroderma	0.000463	0.00644	CbGeAlD
Dasatinib—MAP3K2—connective tissue—systemic scleroderma	0.000458	0.00638	CbGeAlD
Dasatinib—EPHA5—digestive system—systemic scleroderma	0.000455	0.00633	CbGeAlD
Dasatinib—ZAK—tendon—systemic scleroderma	0.000442	0.00616	CbGeAlD
Dasatinib—RIPK2—skin of body—systemic scleroderma	0.000437	0.00608	CbGeAlD
Dasatinib—MAPK14—connective tissue—systemic scleroderma	0.000431	0.006	CbGeAlD
Dasatinib—EPHA3—lung—systemic scleroderma	0.000429	0.00597	CbGeAlD
Dasatinib—SIK1—skin of body—systemic scleroderma	0.000426	0.00594	CbGeAlD
Dasatinib—BTK—tendon—systemic scleroderma	0.000422	0.00587	CbGeAlD
Dasatinib—ERBB3—skin of body—systemic scleroderma	0.000418	0.00582	CbGeAlD
Dasatinib—SIK3—lung—systemic scleroderma	0.000417	0.00581	CbGeAlD
Dasatinib—EPHB4—connective tissue—systemic scleroderma	0.000409	0.00569	CbGeAlD
Dasatinib—JAK2—connective tissue—systemic scleroderma	0.000406	0.00565	CbGeAlD
Dasatinib—EPHB3—digestive system—systemic scleroderma	0.000404	0.00563	CbGeAlD
Dasatinib—FYN—connective tissue—systemic scleroderma	0.0004	0.00557	CbGeAlD
Dasatinib—MAPK14—smooth muscle tissue—systemic scleroderma	0.000394	0.00549	CbGeAlD
Dasatinib—TESK1—tendon—systemic scleroderma	0.000391	0.00544	CbGeAlD
Dasatinib—MAPK14—skin of body—systemic scleroderma	0.000389	0.00542	CbGeAlD
Dasatinib—ZAK—lung—systemic scleroderma	0.000388	0.0054	CbGeAlD
Dasatinib—STK36—tendon—systemic scleroderma	0.000385	0.00536	CbGeAlD
Dasatinib—CSK—digestive system—systemic scleroderma	0.000376	0.00524	CbGeAlD
Dasatinib—EPHB4—smooth muscle tissue—systemic scleroderma	0.000374	0.0052	CbGeAlD
Dasatinib—MAP3K19—lung—systemic scleroderma	0.000372	0.00518	CbGeAlD
Dasatinib—BMPR1B—lung—systemic scleroderma	0.000372	0.00518	CbGeAlD
Dasatinib—HCK—digestive system—systemic scleroderma	0.000371	0.00517	CbGeAlD
Dasatinib—JAK2—smooth muscle tissue—systemic scleroderma	0.000371	0.00517	CbGeAlD
Dasatinib—BTK—lung—systemic scleroderma	0.00037	0.00515	CbGeAlD
Dasatinib—JAK2—skin of body—systemic scleroderma	0.000366	0.0051	CbGeAlD
Dasatinib—FYN—smooth muscle tissue—systemic scleroderma	0.000366	0.0051	CbGeAlD
Dasatinib—TNK2—lung—systemic scleroderma	0.000365	0.00508	CbGeAlD
Dasatinib—FYN—skin of body—systemic scleroderma	0.000361	0.00503	CbGeAlD
Dasatinib—YES1—connective tissue—systemic scleroderma	0.000361	0.00503	CbGeAlD
Dasatinib—STK35—tendon—systemic scleroderma	0.00036	0.00502	CbGeAlD
Dasatinib—CSK—tendon—systemic scleroderma	0.000358	0.00499	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—systemic scleroderma	0.000358	0.00498	CbGeAlD
Dasatinib—TESK1—Enalapril—Lisinopril—systemic scleroderma	0.000356	0.125	CbGdCrCtD
Dasatinib—PDGFRA—connective tissue—systemic scleroderma	0.000354	0.00493	CbGeAlD
Dasatinib—HCK—tendon—systemic scleroderma	0.000354	0.00492	CbGeAlD
Dasatinib—MAP3K3—skin of body—systemic scleroderma	0.000353	0.00492	CbGeAlD
Dasatinib—ABL2—tendon—systemic scleroderma	0.000351	0.00489	CbGeAlD
Dasatinib—RIPK2—digestive system—systemic scleroderma	0.000349	0.00486	CbGeAlD
Dasatinib—SRC—connective tissue—systemic scleroderma	0.000347	0.00484	CbGeAlD
Dasatinib—TESK1—lung—systemic scleroderma	0.000343	0.00478	CbGeAlD
Dasatinib—STK36—lung—systemic scleroderma	0.000338	0.0047	CbGeAlD
Dasatinib—EPHB3—lung—systemic scleroderma	0.000338	0.0047	CbGeAlD
Dasatinib—EPHB6—skin of body—systemic scleroderma	0.000337	0.0047	CbGeAlD
Dasatinib—ERBB3—digestive system—systemic scleroderma	0.000334	0.00465	CbGeAlD
Dasatinib—RIPK2—tendon—systemic scleroderma	0.000332	0.00463	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—systemic scleroderma	0.00033	0.0046	CbGeAlD
Dasatinib—LIMK2—lung—systemic scleroderma	0.000326	0.00454	CbGeAlD
Dasatinib—SIK1—tendon—systemic scleroderma	0.000325	0.00452	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—systemic scleroderma	0.000324	0.00451	CbGeAlD
Dasatinib—EPHA4—tendon—systemic scleroderma	0.000321	0.00447	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—systemic scleroderma	0.000318	0.00442	CbGeAlD
Dasatinib—STK35—lung—systemic scleroderma	0.000316	0.0044	CbGeAlD
Dasatinib—CSK—lung—systemic scleroderma	0.000314	0.00438	CbGeAlD
Dasatinib—SRC—skin of body—systemic scleroderma	0.000314	0.00437	CbGeAlD
Dasatinib—CSF1R—connective tissue—systemic scleroderma	0.000312	0.00434	CbGeAlD
Dasatinib—MAPK14—digestive system—systemic scleroderma	0.000311	0.00433	CbGeAlD
Dasatinib—HCK—lung—systemic scleroderma	0.00031	0.00432	CbGeAlD
Dasatinib—FGR—digestive system—systemic scleroderma	0.00031	0.00432	CbGeAlD
Dasatinib—ABL2—lung—systemic scleroderma	0.000308	0.00429	CbGeAlD
Dasatinib—MAPK14—tendon—systemic scleroderma	0.000296	0.00412	CbGeAlD
Dasatinib—EPHB4—digestive system—systemic scleroderma	0.000295	0.00411	CbGeAlD
Dasatinib—FGR—tendon—systemic scleroderma	0.000295	0.00411	CbGeAlD
Dasatinib—JAK2—digestive system—systemic scleroderma	0.000293	0.00408	CbGeAlD
Dasatinib—RIPK2—lung—systemic scleroderma	0.000292	0.00406	CbGeAlD
Dasatinib—EPHA2—digestive system—systemic scleroderma	0.00029	0.00403	CbGeAlD
Dasatinib—FYN—digestive system—systemic scleroderma	0.000289	0.00402	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—systemic scleroderma	0.000285	0.00397	CbGeAlD
Dasatinib—SIK1—lung—systemic scleroderma	0.000285	0.00397	CbGeAlD
Dasatinib—KIT—connective tissue—systemic scleroderma	0.000283	0.00394	CbGeAlD
Dasatinib—EPHA4—lung—systemic scleroderma	0.000282	0.00393	CbGeAlD
Dasatinib—CSF1R—skin of body—systemic scleroderma	0.000282	0.00392	CbGeAlD
Dasatinib—EPHB4—tendon—systemic scleroderma	0.000281	0.00391	CbGeAlD
Dasatinib—ERBB3—lung—systemic scleroderma	0.000279	0.00389	CbGeAlD
Dasatinib—JAK2—tendon—systemic scleroderma	0.000279	0.00388	CbGeAlD
Dasatinib—PDGFRB—connective tissue—systemic scleroderma	0.000277	0.00385	CbGeAlD
Dasatinib—MAP3K2—lung—systemic scleroderma	0.000277	0.00385	CbGeAlD
Dasatinib—EPHA2—tendon—systemic scleroderma	0.000276	0.00384	CbGeAlD
Dasatinib—FYN—tendon—systemic scleroderma	0.000275	0.00383	CbGeAlD
Dasatinib—MAP3K3—tendon—systemic scleroderma	0.000269	0.00374	CbGeAlD
Dasatinib—MAP4K5—tendon—systemic scleroderma	0.000269	0.00374	CbGeAlD
Dasatinib—YES1—digestive system—systemic scleroderma	0.000261	0.00363	CbGeAlD
Dasatinib—MAPK14—lung—systemic scleroderma	0.00026	0.00362	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—systemic scleroderma	0.000259	0.00361	CbGeAlD
Dasatinib—FGR—lung—systemic scleroderma	0.000259	0.0036	CbGeAlD
Dasatinib—LCK—lung—systemic scleroderma	0.000259	0.0036	CbGeAlD
Dasatinib—EPHB6—tendon—systemic scleroderma	0.000257	0.00358	CbGeAlD
Dasatinib—PDGFRA—digestive system—systemic scleroderma	0.000256	0.00356	CbGeAlD
Dasatinib—KIT—skin of body—systemic scleroderma	0.000256	0.00356	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—systemic scleroderma	0.000253	0.00352	CbGeAlD
Dasatinib—SRC—digestive system—systemic scleroderma	0.000251	0.00349	CbGeAlD
Dasatinib—FMO3—lung—systemic scleroderma	0.00025	0.00348	CbGeAlD
Dasatinib—PDGFRB—skin of body—systemic scleroderma	0.00025	0.00348	CbGeAlD
Dasatinib—YES1—tendon—systemic scleroderma	0.000248	0.00346	CbGeAlD
Dasatinib—ABL1—connective tissue—systemic scleroderma	0.000247	0.00343	CbGeAlD
Dasatinib—EPHB4—lung—systemic scleroderma	0.000246	0.00343	CbGeAlD
Dasatinib—JAK2—lung—systemic scleroderma	0.000245	0.00341	CbGeAlD
Dasatinib—PDGFRA—tendon—systemic scleroderma	0.000244	0.00339	CbGeAlD
Dasatinib—EPHA2—lung—systemic scleroderma	0.000242	0.00337	CbGeAlD
Dasatinib—FYN—lung—systemic scleroderma	0.000241	0.00336	CbGeAlD
Dasatinib—MAP3K3—lung—systemic scleroderma	0.000236	0.00328	CbGeAlD
Dasatinib—MAP4K5—lung—systemic scleroderma	0.000236	0.00328	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—systemic scleroderma	0.000226	0.00314	CbGeAlD
Dasatinib—EPHB6—lung—systemic scleroderma	0.000225	0.00314	CbGeAlD
Dasatinib—CSF1R—digestive system—systemic scleroderma	0.000225	0.00314	CbGeAlD
Dasatinib—ABL1—skin of body—systemic scleroderma	0.000223	0.0031	CbGeAlD
Dasatinib—MAP2K5—tendon—systemic scleroderma	0.00022	0.00306	CbGeAlD
Dasatinib—YES1—lung—systemic scleroderma	0.000218	0.00303	CbGeAlD
Dasatinib—EPHB2—Diflorasone—Mometasone—systemic scleroderma	0.000215	0.0754	CbGdCrCtD
Dasatinib—CSF1R—tendon—systemic scleroderma	0.000214	0.00298	CbGeAlD
Dasatinib—PDGFRA—lung—systemic scleroderma	0.000214	0.00298	CbGeAlD
Dasatinib—SRC—lung—systemic scleroderma	0.00021	0.00292	CbGeAlD
Dasatinib—CYP1B1—connective tissue—systemic scleroderma	0.000209	0.00291	CbGeAlD
Dasatinib—KIT—digestive system—systemic scleroderma	0.000205	0.00285	CbGeAlD
Dasatinib—PDGFRB—digestive system—systemic scleroderma	0.0002	0.00278	CbGeAlD
Dasatinib—MAP2K5—lung—systemic scleroderma	0.000193	0.00268	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—systemic scleroderma	0.000191	0.00266	CbGeAlD
Dasatinib—PDGFRB—tendon—systemic scleroderma	0.00019	0.00265	CbGeAlD
Dasatinib—CYP1B1—skin of body—systemic scleroderma	0.000189	0.00262	CbGeAlD
Dasatinib—CSF1R—lung—systemic scleroderma	0.000188	0.00262	CbGeAlD
Dasatinib—ABL1—digestive system—systemic scleroderma	0.000178	0.00248	CbGeAlD
Dasatinib—KIT—lung—systemic scleroderma	0.000171	0.00238	CbGeAlD
Dasatinib—ABL1—tendon—systemic scleroderma	0.000169	0.00236	CbGeAlD
Dasatinib—PDGFRB—lung—systemic scleroderma	0.000167	0.00232	CbGeAlD
Dasatinib—CYP1B1—digestive system—systemic scleroderma	0.000151	0.0021	CbGeAlD
Dasatinib—ABCB1—blood vessel—systemic scleroderma	0.00015	0.00208	CbGeAlD
Dasatinib—ABL1—lung—systemic scleroderma	0.000149	0.00207	CbGeAlD
Dasatinib—CYP1B1—tendon—systemic scleroderma	0.000144	0.002	CbGeAlD
Dasatinib—CYP1A1—skin of body—systemic scleroderma	0.000133	0.00186	CbGeAlD
Dasatinib—CYP1B1—lung—systemic scleroderma	0.000126	0.00175	CbGeAlD
Dasatinib—EPHB2—Diflorasone—Prednisone—systemic scleroderma	0.000117	0.0411	CbGdCrCtD
Dasatinib—CYP1A2—digestive system—systemic scleroderma	0.000108	0.0015	CbGeAlD
Dasatinib—CYP1A1—digestive system—systemic scleroderma	0.000107	0.00148	CbGeAlD
Dasatinib—CYP3A5—digestive system—systemic scleroderma	0.000104	0.00145	CbGeAlD
Dasatinib—ABCG2—lung—systemic scleroderma	9.38e-05	0.00131	CbGeAlD
Dasatinib—CYP1A2—lung—systemic scleroderma	9.03e-05	0.00126	CbGeAlD
Dasatinib—CYP1A1—lung—systemic scleroderma	8.9e-05	0.00124	CbGeAlD
Dasatinib—TESK1—Betamethasone—Mometasone—systemic scleroderma	8.74e-05	0.0307	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Mometasone—systemic scleroderma	8.74e-05	0.0307	CbGdCrCtD
Dasatinib—CYP3A5—lung—systemic scleroderma	8.71e-05	0.00121	CbGeAlD
Dasatinib—CYP3A4—digestive system—systemic scleroderma	7.82e-05	0.00109	CbGeAlD
Dasatinib—Palpitations—Mycophenolate mofetil—systemic scleroderma	6.81e-05	0.000571	CcSEcCtD
Dasatinib—Weight decreased—Prednisone—systemic scleroderma	6.78e-05	0.000569	CcSEcCtD
Dasatinib—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	6.77e-05	0.000568	CcSEcCtD
Dasatinib—Cough—Mycophenolate mofetil—systemic scleroderma	6.73e-05	0.000564	CcSEcCtD
Dasatinib—Hypotension—Lisinopril—systemic scleroderma	6.71e-05	0.000563	CcSEcCtD
Dasatinib—Dizziness—Captopril—systemic scleroderma	6.7e-05	0.000562	CcSEcCtD
Dasatinib—Convulsion—Mycophenolate mofetil—systemic scleroderma	6.68e-05	0.00056	CcSEcCtD
Dasatinib—PKMYT1—Danazol—Prednisone—systemic scleroderma	6.65e-05	0.0233	CbGdCrCtD
Dasatinib—Hypertension—Mycophenolate mofetil—systemic scleroderma	6.65e-05	0.000558	CcSEcCtD
Dasatinib—Urticaria—Leflunomide—systemic scleroderma	6.64e-05	0.000557	CcSEcCtD
Dasatinib—Abdominal pain—Leflunomide—systemic scleroderma	6.6e-05	0.000554	CcSEcCtD
Dasatinib—Body temperature increased—Leflunomide—systemic scleroderma	6.6e-05	0.000554	CcSEcCtD
Dasatinib—Acute coronary syndrome—Prednisone—systemic scleroderma	6.59e-05	0.000553	CcSEcCtD
Dasatinib—Feeling abnormal—Mycophenolic acid—systemic scleroderma	6.57e-05	0.000551	CcSEcCtD
Dasatinib—Chest pain—Mycophenolate mofetil—systemic scleroderma	6.56e-05	0.00055	CcSEcCtD
Dasatinib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	6.56e-05	0.00055	CcSEcCtD
Dasatinib—Myalgia—Mycophenolate mofetil—systemic scleroderma	6.56e-05	0.00055	CcSEcCtD
Dasatinib—Myocardial infarction—Prednisone—systemic scleroderma	6.55e-05	0.00055	CcSEcCtD
Dasatinib—Neuropathy peripheral—Prednisone—systemic scleroderma	6.55e-05	0.00055	CcSEcCtD
Dasatinib—Breast disorder—Methotrexate—systemic scleroderma	6.55e-05	0.00055	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	6.54e-05	0.000549	CcSEcCtD
Dasatinib—Anxiety—Mycophenolate mofetil—systemic scleroderma	6.54e-05	0.000548	CcSEcCtD
Dasatinib—Hypersensitivity—Azathioprine—systemic scleroderma	6.52e-05	0.000547	CcSEcCtD
Dasatinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	6.52e-05	0.000547	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	6.52e-05	0.000547	CcSEcCtD
Dasatinib—Insomnia—Lisinopril—systemic scleroderma	6.49e-05	0.000545	CcSEcCtD
Dasatinib—Discomfort—Mycophenolate mofetil—systemic scleroderma	6.48e-05	0.000544	CcSEcCtD
Dasatinib—Vomiting—Captopril—systemic scleroderma	6.45e-05	0.000541	CcSEcCtD
Dasatinib—Dyspnoea—Lisinopril—systemic scleroderma	6.4e-05	0.000537	CcSEcCtD
Dasatinib—Rash—Captopril—systemic scleroderma	6.39e-05	0.000536	CcSEcCtD
Dasatinib—Dermatitis—Captopril—systemic scleroderma	6.39e-05	0.000536	CcSEcCtD
Dasatinib—Somnolence—Lisinopril—systemic scleroderma	6.38e-05	0.000535	CcSEcCtD
Dasatinib—Headache—Captopril—systemic scleroderma	6.35e-05	0.000533	CcSEcCtD
Dasatinib—Confusional state—Mycophenolate mofetil—systemic scleroderma	6.34e-05	0.000532	CcSEcCtD
Dasatinib—Dyspepsia—Lisinopril—systemic scleroderma	6.32e-05	0.00053	CcSEcCtD
Dasatinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	6.3e-05	0.000528	CcSEcCtD
Dasatinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	6.3e-05	0.000528	CcSEcCtD
Dasatinib—Oedema—Mycophenolate mofetil—systemic scleroderma	6.29e-05	0.000528	CcSEcCtD
Dasatinib—Asthma—Methotrexate—systemic scleroderma	6.27e-05	0.000526	CcSEcCtD
Dasatinib—Infection—Mycophenolate mofetil—systemic scleroderma	6.25e-05	0.000524	CcSEcCtD
Dasatinib—Decreased appetite—Lisinopril—systemic scleroderma	6.24e-05	0.000523	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	6.2e-05	0.00052	CcSEcCtD
Dasatinib—Fatigue—Lisinopril—systemic scleroderma	6.19e-05	0.000519	CcSEcCtD
Dasatinib—Shock—Mycophenolate mofetil—systemic scleroderma	6.19e-05	0.000519	CcSEcCtD
Dasatinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	6.17e-05	0.000517	CcSEcCtD
Dasatinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	6.16e-05	0.000517	CcSEcCtD
Dasatinib—Hypersensitivity—Leflunomide—systemic scleroderma	6.16e-05	0.000516	CcSEcCtD
Dasatinib—Pancreatitis—Methotrexate—systemic scleroderma	6.14e-05	0.000515	CcSEcCtD
Dasatinib—Pain—Lisinopril—systemic scleroderma	6.14e-05	0.000515	CcSEcCtD
Dasatinib—Constipation—Lisinopril—systemic scleroderma	6.14e-05	0.000515	CcSEcCtD
Dasatinib—Tachycardia—Mycophenolate mofetil—systemic scleroderma	6.14e-05	0.000515	CcSEcCtD
Dasatinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	6.11e-05	0.000512	CcSEcCtD
Dasatinib—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	6.08e-05	0.00051	CcSEcCtD
Dasatinib—Diarrhoea—Azathioprine—systemic scleroderma	6.05e-05	0.000508	CcSEcCtD
Dasatinib—Haemoglobin—Prednisone—systemic scleroderma	6.03e-05	0.000506	CcSEcCtD
Dasatinib—Nausea—Captopril—systemic scleroderma	6.02e-05	0.000505	CcSEcCtD
Dasatinib—Haemorrhage—Prednisone—systemic scleroderma	6e-05	0.000503	CcSEcCtD
Dasatinib—Anorexia—Mycophenolate mofetil—systemic scleroderma	6e-05	0.000503	CcSEcCtD
Dasatinib—Asthenia—Leflunomide—systemic scleroderma	5.99e-05	0.000503	CcSEcCtD
Dasatinib—Pancytopenia—Methotrexate—systemic scleroderma	5.95e-05	0.000499	CcSEcCtD
Dasatinib—Feeling abnormal—Lisinopril—systemic scleroderma	5.92e-05	0.000496	CcSEcCtD
Dasatinib—Pruritus—Leflunomide—systemic scleroderma	5.91e-05	0.000496	CcSEcCtD
Dasatinib—Connective tissue disorder—Prednisone—systemic scleroderma	5.9e-05	0.000495	CcSEcCtD
Dasatinib—Hypotension—Mycophenolate mofetil—systemic scleroderma	5.88e-05	0.000493	CcSEcCtD
Dasatinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	5.87e-05	0.000492	CcSEcCtD
Dasatinib—Neutropenia—Methotrexate—systemic scleroderma	5.86e-05	0.000491	CcSEcCtD
Dasatinib—Dizziness—Azathioprine—systemic scleroderma	5.85e-05	0.000491	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	5.82e-05	0.000488	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	5.73e-05	0.000481	CcSEcCtD
Dasatinib—Photosensitivity reaction—Methotrexate—systemic scleroderma	5.72e-05	0.00048	CcSEcCtD
Dasatinib—Asthenia—Mycophenolic acid—systemic scleroderma	5.72e-05	0.00048	CcSEcCtD
Dasatinib—Diarrhoea—Leflunomide—systemic scleroderma	5.72e-05	0.000479	CcSEcCtD
Dasatinib—Urticaria—Lisinopril—systemic scleroderma	5.7e-05	0.000478	CcSEcCtD
Dasatinib—Insomnia—Mycophenolate mofetil—systemic scleroderma	5.69e-05	0.000477	CcSEcCtD
Dasatinib—Abdominal pain—Lisinopril—systemic scleroderma	5.68e-05	0.000476	CcSEcCtD
Dasatinib—Body temperature increased—Lisinopril—systemic scleroderma	5.68e-05	0.000476	CcSEcCtD
Dasatinib—Pruritus—Mycophenolic acid—systemic scleroderma	5.64e-05	0.000473	CcSEcCtD
Dasatinib—Vomiting—Azathioprine—systemic scleroderma	5.63e-05	0.000472	CcSEcCtD
Dasatinib—Pneumonia—Methotrexate—systemic scleroderma	5.62e-05	0.000471	CcSEcCtD
Dasatinib—Eye disorder—Prednisone—systemic scleroderma	5.61e-05	0.00047	CcSEcCtD
Dasatinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	5.61e-05	0.00047	CcSEcCtD
Dasatinib—Somnolence—Mycophenolate mofetil—systemic scleroderma	5.59e-05	0.000469	CcSEcCtD
Dasatinib—Infestation NOS—Methotrexate—systemic scleroderma	5.59e-05	0.000469	CcSEcCtD
Dasatinib—Infestation—Methotrexate—systemic scleroderma	5.59e-05	0.000469	CcSEcCtD
Dasatinib—Rash—Azathioprine—systemic scleroderma	5.58e-05	0.000468	CcSEcCtD
Dasatinib—Dermatitis—Azathioprine—systemic scleroderma	5.57e-05	0.000467	CcSEcCtD
Dasatinib—Flushing—Prednisone—systemic scleroderma	5.57e-05	0.000467	CcSEcCtD
Dasatinib—Headache—Azathioprine—systemic scleroderma	5.54e-05	0.000465	CcSEcCtD
Dasatinib—ABCB1—digestive system—systemic scleroderma	5.54e-05	0.000771	CbGeAlD
Dasatinib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	5.54e-05	0.000464	CcSEcCtD
Dasatinib—Dizziness—Leflunomide—systemic scleroderma	5.52e-05	0.000463	CcSEcCtD
Dasatinib—Renal failure—Methotrexate—systemic scleroderma	5.49e-05	0.000461	CcSEcCtD
Dasatinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	5.47e-05	0.000459	CcSEcCtD
Dasatinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	5.45e-05	0.000457	CcSEcCtD
Dasatinib—Stomatitis—Methotrexate—systemic scleroderma	5.45e-05	0.000457	CcSEcCtD
Dasatinib—Angiopathy—Prednisone—systemic scleroderma	5.44e-05	0.000457	CcSEcCtD
Dasatinib—Conjunctivitis—Methotrexate—systemic scleroderma	5.43e-05	0.000456	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	5.43e-05	0.000455	CcSEcCtD
Dasatinib—Immune system disorder—Prednisone—systemic scleroderma	5.42e-05	0.000455	CcSEcCtD
Dasatinib—Constipation—Mycophenolate mofetil—systemic scleroderma	5.38e-05	0.000451	CcSEcCtD
Dasatinib—Pain—Mycophenolate mofetil—systemic scleroderma	5.38e-05	0.000451	CcSEcCtD
Dasatinib—Arrhythmia—Prednisone—systemic scleroderma	5.36e-05	0.00045	CcSEcCtD
Dasatinib—Haematuria—Methotrexate—systemic scleroderma	5.33e-05	0.000447	CcSEcCtD
Dasatinib—Vomiting—Leflunomide—systemic scleroderma	5.31e-05	0.000446	CcSEcCtD
Dasatinib—Alopecia—Prednisone—systemic scleroderma	5.3e-05	0.000445	CcSEcCtD
Dasatinib—Hypersensitivity—Lisinopril—systemic scleroderma	5.29e-05	0.000444	CcSEcCtD
Dasatinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	5.28e-05	0.000443	CcSEcCtD
Dasatinib—Dizziness—Mycophenolic acid—systemic scleroderma	5.27e-05	0.000442	CcSEcCtD
Dasatinib—Epistaxis—Methotrexate—systemic scleroderma	5.27e-05	0.000442	CcSEcCtD
Dasatinib—Rash—Leflunomide—systemic scleroderma	5.27e-05	0.000442	CcSEcCtD
Dasatinib—Dermatitis—Leflunomide—systemic scleroderma	5.26e-05	0.000441	CcSEcCtD
Dasatinib—Mental disorder—Prednisone—systemic scleroderma	5.26e-05	0.000441	CcSEcCtD
Dasatinib—Nausea—Azathioprine—systemic scleroderma	5.25e-05	0.000441	CcSEcCtD
Dasatinib—Headache—Leflunomide—systemic scleroderma	5.23e-05	0.000439	CcSEcCtD
Dasatinib—Erythema—Prednisone—systemic scleroderma	5.22e-05	0.000438	CcSEcCtD
Dasatinib—Malnutrition—Prednisone—systemic scleroderma	5.22e-05	0.000438	CcSEcCtD
Dasatinib—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	5.18e-05	0.000435	CcSEcCtD
Dasatinib—Asthenia—Lisinopril—systemic scleroderma	5.15e-05	0.000432	CcSEcCtD
Dasatinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	5.14e-05	0.000431	CcSEcCtD
Dasatinib—Pruritus—Lisinopril—systemic scleroderma	5.08e-05	0.000426	CcSEcCtD
Dasatinib—Vomiting—Mycophenolic acid—systemic scleroderma	5.07e-05	0.000425	CcSEcCtD
Dasatinib—Haemoglobin—Methotrexate—systemic scleroderma	5.04e-05	0.000423	CcSEcCtD
Dasatinib—Rash—Mycophenolic acid—systemic scleroderma	5.03e-05	0.000422	CcSEcCtD
Dasatinib—Dermatitis—Mycophenolic acid—systemic scleroderma	5.02e-05	0.000421	CcSEcCtD
Dasatinib—Haemorrhage—Methotrexate—systemic scleroderma	5.02e-05	0.000421	CcSEcCtD
Dasatinib—Hepatitis—Methotrexate—systemic scleroderma	5.02e-05	0.000421	CcSEcCtD
Dasatinib—Urticaria—Mycophenolate mofetil—systemic scleroderma	5e-05	0.000419	CcSEcCtD
Dasatinib—Headache—Mycophenolic acid—systemic scleroderma	4.99e-05	0.000419	CcSEcCtD
Dasatinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	4.97e-05	0.000417	CcSEcCtD
Dasatinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	4.97e-05	0.000417	CcSEcCtD
Dasatinib—Nausea—Leflunomide—systemic scleroderma	4.96e-05	0.000416	CcSEcCtD
Dasatinib—Urinary tract disorder—Methotrexate—systemic scleroderma	4.95e-05	0.000415	CcSEcCtD
Dasatinib—Vision blurred—Prednisone—systemic scleroderma	4.92e-05	0.000413	CcSEcCtD
Dasatinib—Urethral disorder—Methotrexate—systemic scleroderma	4.92e-05	0.000412	CcSEcCtD
Dasatinib—Diarrhoea—Lisinopril—systemic scleroderma	4.91e-05	0.000412	CcSEcCtD
Dasatinib—Ill-defined disorder—Prednisone—systemic scleroderma	4.85e-05	0.000407	CcSEcCtD
Dasatinib—Visual impairment—Methotrexate—systemic scleroderma	4.83e-05	0.000405	CcSEcCtD
Dasatinib—Anaemia—Prednisone—systemic scleroderma	4.83e-05	0.000405	CcSEcCtD
Dasatinib—TESK1—Betamethasone—Prednisone—systemic scleroderma	4.77e-05	0.0167	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Prednisone—systemic scleroderma	4.77e-05	0.0167	CbGdCrCtD
Dasatinib—Dizziness—Lisinopril—systemic scleroderma	4.75e-05	0.000398	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—systemic scleroderma	4.74e-05	0.000398	CcSEcCtD
Dasatinib—Nausea—Mycophenolic acid—systemic scleroderma	4.73e-05	0.000397	CcSEcCtD
Dasatinib—Malaise—Prednisone—systemic scleroderma	4.71e-05	0.000395	CcSEcCtD
Dasatinib—Vertigo—Prednisone—systemic scleroderma	4.69e-05	0.000394	CcSEcCtD
Dasatinib—Eye disorder—Methotrexate—systemic scleroderma	4.69e-05	0.000393	CcSEcCtD
Dasatinib—Syncope—Prednisone—systemic scleroderma	4.68e-05	0.000393	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—systemic scleroderma	4.68e-05	0.000392	CcSEcCtD
Dasatinib—Cardiac disorder—Methotrexate—systemic scleroderma	4.65e-05	0.00039	CcSEcCtD
Dasatinib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	4.63e-05	0.000389	CcSEcCtD
Dasatinib—ABCB1—lung—systemic scleroderma	4.62e-05	0.000644	CbGeAlD
Dasatinib—Loss of consciousness—Prednisone—systemic scleroderma	4.59e-05	0.000385	CcSEcCtD
Dasatinib—Vomiting—Lisinopril—systemic scleroderma	4.56e-05	0.000383	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—systemic scleroderma	4.55e-05	0.000382	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—systemic scleroderma	4.53e-05	0.00038	CcSEcCtD
Dasatinib—Rash—Lisinopril—systemic scleroderma	4.53e-05	0.00038	CcSEcCtD
Dasatinib—Convulsion—Prednisone—systemic scleroderma	4.53e-05	0.00038	CcSEcCtD
Dasatinib—Dermatitis—Lisinopril—systemic scleroderma	4.52e-05	0.000379	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—systemic scleroderma	4.52e-05	0.000379	CcSEcCtD
Dasatinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	4.51e-05	0.000379	CcSEcCtD
Dasatinib—Hypertension—Prednisone—systemic scleroderma	4.51e-05	0.000378	CcSEcCtD
Dasatinib—Chills—Methotrexate—systemic scleroderma	4.5e-05	0.000377	CcSEcCtD
Dasatinib—Headache—Lisinopril—systemic scleroderma	4.5e-05	0.000377	CcSEcCtD
Dasatinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	4.45e-05	0.000373	CcSEcCtD
Dasatinib—Arthralgia—Prednisone—systemic scleroderma	4.45e-05	0.000373	CcSEcCtD
Dasatinib—Myalgia—Prednisone—systemic scleroderma	4.45e-05	0.000373	CcSEcCtD
Dasatinib—Anxiety—Prednisone—systemic scleroderma	4.43e-05	0.000372	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—systemic scleroderma	4.43e-05	0.000372	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	4.42e-05	0.00037	CcSEcCtD
Dasatinib—Discomfort—Prednisone—systemic scleroderma	4.39e-05	0.000369	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—systemic scleroderma	4.39e-05	0.000369	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—systemic scleroderma	4.37e-05	0.000366	CcSEcCtD
Dasatinib—Erythema—Methotrexate—systemic scleroderma	4.37e-05	0.000366	CcSEcCtD
Dasatinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	4.3e-05	0.000361	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—systemic scleroderma	4.28e-05	0.000359	CcSEcCtD
Dasatinib—Nausea—Lisinopril—systemic scleroderma	4.26e-05	0.000358	CcSEcCtD
Dasatinib—Oedema—Prednisone—systemic scleroderma	4.26e-05	0.000358	CcSEcCtD
Dasatinib—Infection—Prednisone—systemic scleroderma	4.24e-05	0.000355	CcSEcCtD
Dasatinib—Shock—Prednisone—systemic scleroderma	4.19e-05	0.000352	CcSEcCtD
Dasatinib—Nervous system disorder—Prednisone—systemic scleroderma	4.18e-05	0.000351	CcSEcCtD
Dasatinib—Tachycardia—Prednisone—systemic scleroderma	4.16e-05	0.000349	CcSEcCtD
Dasatinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.16e-05	0.000349	CcSEcCtD
Dasatinib—Skin disorder—Prednisone—systemic scleroderma	4.14e-05	0.000347	CcSEcCtD
Dasatinib—Hyperhidrosis—Prednisone—systemic scleroderma	4.12e-05	0.000346	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—systemic scleroderma	4.11e-05	0.000345	CcSEcCtD
Dasatinib—Anorexia—Prednisone—systemic scleroderma	4.06e-05	0.000341	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—systemic scleroderma	4.05e-05	0.00034	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—systemic scleroderma	4.04e-05	0.000338	CcSEcCtD
Dasatinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	4e-05	0.000335	CcSEcCtD
Dasatinib—Rash—Mycophenolate mofetil—systemic scleroderma	3.97e-05	0.000333	CcSEcCtD
Dasatinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.96e-05	0.000332	CcSEcCtD
Dasatinib—Headache—Mycophenolate mofetil—systemic scleroderma	3.94e-05	0.000331	CcSEcCtD
Dasatinib—Malaise—Methotrexate—systemic scleroderma	3.94e-05	0.00033	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—systemic scleroderma	3.92e-05	0.000329	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	3.88e-05	0.000326	CcSEcCtD
Dasatinib—Insomnia—Prednisone—systemic scleroderma	3.86e-05	0.000323	CcSEcCtD
Dasatinib—Cough—Methotrexate—systemic scleroderma	3.81e-05	0.00032	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—systemic scleroderma	3.78e-05	0.000317	CcSEcCtD
Dasatinib—Dyspepsia—Prednisone—systemic scleroderma	3.75e-05	0.000315	CcSEcCtD
Dasatinib—Nausea—Mycophenolate mofetil—systemic scleroderma	3.74e-05	0.000313	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—systemic scleroderma	3.72e-05	0.000312	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—systemic scleroderma	3.72e-05	0.000312	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—systemic scleroderma	3.72e-05	0.000312	CcSEcCtD
Dasatinib—Decreased appetite—Prednisone—systemic scleroderma	3.71e-05	0.000311	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	3.69e-05	0.00031	CcSEcCtD
Dasatinib—Fatigue—Prednisone—systemic scleroderma	3.68e-05	0.000308	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—systemic scleroderma	3.67e-05	0.000308	CcSEcCtD
Dasatinib—Constipation—Prednisone—systemic scleroderma	3.65e-05	0.000306	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—systemic scleroderma	3.59e-05	0.000301	CcSEcCtD
Dasatinib—Infection—Methotrexate—systemic scleroderma	3.54e-05	0.000297	CcSEcCtD
Dasatinib—Feeling abnormal—Prednisone—systemic scleroderma	3.51e-05	0.000295	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—systemic scleroderma	3.49e-05	0.000293	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—systemic scleroderma	3.49e-05	0.000293	CcSEcCtD
Dasatinib—Gastrointestinal pain—Prednisone—systemic scleroderma	3.49e-05	0.000292	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—systemic scleroderma	3.46e-05	0.00029	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—systemic scleroderma	3.44e-05	0.000289	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—systemic scleroderma	3.4e-05	0.000285	CcSEcCtD
Dasatinib—Urticaria—Prednisone—systemic scleroderma	3.39e-05	0.000284	CcSEcCtD
Dasatinib—Body temperature increased—Prednisone—systemic scleroderma	3.37e-05	0.000283	CcSEcCtD
Dasatinib—Abdominal pain—Prednisone—systemic scleroderma	3.37e-05	0.000283	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—systemic scleroderma	3.33e-05	0.000279	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3.25e-05	0.000272	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—systemic scleroderma	3.22e-05	0.00027	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—systemic scleroderma	3.18e-05	0.000266	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—systemic scleroderma	3.17e-05	0.000266	CcSEcCtD
Dasatinib—Hypersensitivity—Prednisone—systemic scleroderma	3.14e-05	0.000263	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—systemic scleroderma	3.14e-05	0.000263	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—systemic scleroderma	3.1e-05	0.00026	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	3.08e-05	0.000258	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—systemic scleroderma	3.07e-05	0.000258	CcSEcCtD
Dasatinib—Asthenia—Prednisone—systemic scleroderma	3.06e-05	0.000257	CcSEcCtD
Dasatinib—Pain—Methotrexate—systemic scleroderma	3.05e-05	0.000256	CcSEcCtD
Dasatinib—Pruritus—Prednisone—systemic scleroderma	3.02e-05	0.000253	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—systemic scleroderma	2.94e-05	0.000246	CcSEcCtD
Dasatinib—Diarrhoea—Prednisone—systemic scleroderma	2.92e-05	0.000245	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.91e-05	0.000244	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—systemic scleroderma	2.83e-05	0.000237	CcSEcCtD
Dasatinib—Dizziness—Prednisone—systemic scleroderma	2.82e-05	0.000236	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—systemic scleroderma	2.82e-05	0.000236	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—systemic scleroderma	2.82e-05	0.000236	CcSEcCtD
Dasatinib—Vomiting—Prednisone—systemic scleroderma	2.71e-05	0.000227	CcSEcCtD
Dasatinib—Rash—Prednisone—systemic scleroderma	2.69e-05	0.000225	CcSEcCtD
Dasatinib—Dermatitis—Prednisone—systemic scleroderma	2.69e-05	0.000225	CcSEcCtD
Dasatinib—Headache—Prednisone—systemic scleroderma	2.67e-05	0.000224	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—systemic scleroderma	2.63e-05	0.00022	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—systemic scleroderma	2.56e-05	0.000214	CcSEcCtD
Dasatinib—Nausea—Prednisone—systemic scleroderma	2.53e-05	0.000212	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—systemic scleroderma	2.52e-05	0.000211	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—systemic scleroderma	2.44e-05	0.000204	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—systemic scleroderma	2.36e-05	0.000198	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—systemic scleroderma	2.27e-05	0.00019	CcSEcCtD
Dasatinib—Rash—Methotrexate—systemic scleroderma	2.25e-05	0.000188	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—systemic scleroderma	2.24e-05	0.000188	CcSEcCtD
Dasatinib—Headache—Methotrexate—systemic scleroderma	2.23e-05	0.000187	CcSEcCtD
Dasatinib—Nausea—Methotrexate—systemic scleroderma	2.12e-05	0.000178	CcSEcCtD
Dasatinib—LYN—Signaling Pathways—RHOB—systemic scleroderma	6.99e-06	5.76e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CTLA4—systemic scleroderma	6.98e-06	5.75e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—MMP2—systemic scleroderma	6.98e-06	5.75e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—MMP2—systemic scleroderma	6.95e-06	5.72e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—HLA-DQB1—systemic scleroderma	6.92e-06	5.7e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—HLA-DQB1—systemic scleroderma	6.91e-06	5.69e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CTLA4—systemic scleroderma	6.91e-06	5.69e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—RHOB—systemic scleroderma	6.88e-06	5.67e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—HSPG2—systemic scleroderma	6.88e-06	5.67e-05	CbGpPWpGaD
Dasatinib—JAK2—Axon guidance—MMP9—systemic scleroderma	6.88e-06	5.67e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—MMP2—systemic scleroderma	6.87e-06	5.66e-05	CbGpPWpGaD
Dasatinib—CSK—Immune System—IL1B—systemic scleroderma	6.86e-06	5.65e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—HSPG2—systemic scleroderma	6.83e-06	5.63e-05	CbGpPWpGaD
Dasatinib—LCK—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	6.75e-06	5.56e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HSPG2—systemic scleroderma	6.73e-06	5.55e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IRF8—systemic scleroderma	6.72e-06	5.53e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD247—systemic scleroderma	6.72e-06	5.53e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—ITGAM—systemic scleroderma	6.72e-06	5.53e-05	CbGpPWpGaD
Dasatinib—SRC—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	6.71e-06	5.53e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CTLA4—systemic scleroderma	6.65e-06	5.48e-05	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—IL1B—systemic scleroderma	6.64e-06	5.47e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—RHOB—systemic scleroderma	6.63e-06	5.46e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—MMP2—systemic scleroderma	6.62e-06	5.45e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CSK—systemic scleroderma	6.6e-06	5.43e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HSPG2—systemic scleroderma	6.59e-06	5.43e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL1A—systemic scleroderma	6.57e-06	5.42e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CTLA4—systemic scleroderma	6.57e-06	5.41e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SMAD7—systemic scleroderma	6.56e-06	5.4e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HLA-DQB1—systemic scleroderma	6.55e-06	5.4e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—RHOB—systemic scleroderma	6.54e-06	5.39e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—CD40LG—systemic scleroderma	6.54e-06	5.38e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—MMP2—systemic scleroderma	6.53e-06	5.38e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—CD40LG—systemic scleroderma	6.53e-06	5.38e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CSK—systemic scleroderma	6.5e-06	5.36e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HSPG2—systemic scleroderma	6.49e-06	5.35e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—MMP1—systemic scleroderma	6.42e-06	5.29e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—NOS3—systemic scleroderma	6.41e-06	5.28e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—NOS3—systemic scleroderma	6.38e-06	5.26e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CSK—systemic scleroderma	6.37e-06	5.25e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—NOS3—systemic scleroderma	6.32e-06	5.2e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—TNFAIP3—systemic scleroderma	6.29e-06	5.18e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CSK—systemic scleroderma	6.27e-06	5.16e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—HSPG2—systemic scleroderma	6.26e-06	5.16e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HSPG2—systemic scleroderma	6.25e-06	5.15e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—EDN1—systemic scleroderma	6.23e-06	5.13e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL1A—systemic scleroderma	6.22e-06	5.13e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—BLK—systemic scleroderma	6.22e-06	5.12e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CD247—systemic scleroderma	6.2e-06	5.11e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—CD40LG—systemic scleroderma	6.19e-06	5.1e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EDN1—systemic scleroderma	6.19e-06	5.1e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HSPG2—systemic scleroderma	6.17e-06	5.08e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—NOS3—systemic scleroderma	6.08e-06	5.01e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.07e-06	5e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CSK—systemic scleroderma	6.04e-06	4.97e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—NOS3—systemic scleroderma	6e-06	4.95e-05	CbGpPWpGaD
Dasatinib—SRC—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	5.97e-06	4.92e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CSK—systemic scleroderma	5.96e-06	4.91e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—MMP9—systemic scleroderma	5.94e-06	4.89e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HLA-DQB1—systemic scleroderma	5.9e-06	4.86e-05	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—IL1B—systemic scleroderma	5.9e-06	4.86e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—CCL2—systemic scleroderma	5.85e-06	4.82e-05	CbGpPWpGaD
Dasatinib—YES1—Developmental Biology—TGFB1—systemic scleroderma	5.8e-06	4.78e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—HLA-DQB1—systemic scleroderma	5.78e-06	4.76e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CTLA4—systemic scleroderma	5.75e-06	4.74e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	5.75e-06	4.74e-05	CbGpPWpGaD
Dasatinib—BTK—Immune System—IL1B—systemic scleroderma	5.74e-06	4.73e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RHOB—systemic scleroderma	5.73e-06	4.72e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—NOS3—systemic scleroderma	5.71e-06	4.71e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—HLA-DQB1—systemic scleroderma	5.69e-06	4.69e-05	CbGpPWpGaD
Dasatinib—YES1—Hemostasis—TGFB1—systemic scleroderma	5.69e-06	4.69e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—CCL2—systemic scleroderma	5.66e-06	4.67e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EDN1—systemic scleroderma	5.66e-06	4.66e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EDN1—systemic scleroderma	5.65e-06	4.66e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL1A—systemic scleroderma	5.61e-06	4.62e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—CD40LG—systemic scleroderma	5.57e-06	4.59e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL1A—systemic scleroderma	5.49e-06	4.52e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HLA-DQB1—systemic scleroderma	5.48e-06	4.51e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL1A—systemic scleroderma	5.46e-06	4.5e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—CD40LG—systemic scleroderma	5.46e-06	4.5e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EDN1—systemic scleroderma	5.45e-06	4.49e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CD40LG—systemic scleroderma	5.43e-06	4.47e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HLA-DQB1—systemic scleroderma	5.41e-06	4.45e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HSPG2—systemic scleroderma	5.4e-06	4.45e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL1A—systemic scleroderma	5.4e-06	4.45e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CD40LG—systemic scleroderma	5.37e-06	4.43e-05	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—MMP9—systemic scleroderma	5.33e-06	4.39e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—IL1B—systemic scleroderma	5.27e-06	4.34e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—NOS3—systemic scleroderma	5.26e-06	4.33e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—MMP9—systemic scleroderma	5.25e-06	4.32e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—MMP9—systemic scleroderma	5.22e-06	4.3e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CSK—systemic scleroderma	5.22e-06	4.3e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—CTGF—systemic scleroderma	5.22e-06	4.3e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—NOS3—systemic scleroderma	5.21e-06	4.29e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL1A—systemic scleroderma	5.2e-06	4.29e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD40LG—systemic scleroderma	5.17e-06	4.26e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—MMP9—systemic scleroderma	5.17e-06	4.25e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL1A—systemic scleroderma	5.14e-06	4.23e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD40LG—systemic scleroderma	5.11e-06	4.21e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CTLA4—systemic scleroderma	5.09e-06	4.19e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RHOB—systemic scleroderma	5.07e-06	4.18e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—MMP2—systemic scleroderma	5.07e-06	4.17e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—NOS3—systemic scleroderma	5.06e-06	4.17e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—NOS3—systemic scleroderma	5.05e-06	4.16e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—MMP9—systemic scleroderma	4.97e-06	4.1e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL1B—systemic scleroderma	4.96e-06	4.09e-05	CbGpPWpGaD
Dasatinib—CSK—Disease—TGFB1—systemic scleroderma	4.92e-06	4.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—MMP9—systemic scleroderma	4.91e-06	4.04e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—TGFB1—systemic scleroderma	4.89e-06	4.03e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EDN1—systemic scleroderma	4.79e-06	3.94e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HSPG2—systemic scleroderma	4.78e-06	3.94e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL1B—systemic scleroderma	4.77e-06	3.93e-05	CbGpPWpGaD
Dasatinib—STAT5B—Disease—TGFB1—systemic scleroderma	4.77e-06	3.93e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL1B—systemic scleroderma	4.76e-06	3.92e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—NOS3—systemic scleroderma	4.74e-06	3.91e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—CTGF—systemic scleroderma	4.74e-06	3.91e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—HLA-DQB1—systemic scleroderma	4.74e-06	3.9e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—NOS3—systemic scleroderma	4.65e-06	3.83e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CSK—systemic scleroderma	4.62e-06	3.81e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.6e-06	3.79e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL1A—systemic scleroderma	4.5e-06	3.71e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—HSPG2—systemic scleroderma	4.49e-06	3.7e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD40LG—systemic scleroderma	4.47e-06	3.68e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL1B—systemic scleroderma	4.37e-06	3.6e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—TGFB1—systemic scleroderma	4.32e-06	3.56e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	4.3e-06	3.55e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EDN1—systemic scleroderma	4.27e-06	3.52e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—TGFB1—systemic scleroderma	4.26e-06	3.51e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TGFB1—systemic scleroderma	4.24e-06	3.49e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—HSPG2—systemic scleroderma	4.24e-06	3.49e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—CCL2—systemic scleroderma	4.23e-06	3.48e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TGFB1—systemic scleroderma	4.22e-06	3.48e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—HLA-DQB1—systemic scleroderma	4.19e-06	3.45e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—MMP9—systemic scleroderma	4.18e-06	3.45e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TGFB1—systemic scleroderma	4.18e-06	3.44e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—TGFB1—systemic scleroderma	4.1e-06	3.38e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—MMP9—systemic scleroderma	4.05e-06	3.34e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EDN1—systemic scleroderma	4.05e-06	3.33e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—TGFB1—systemic scleroderma	4.05e-06	3.33e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TGFB1—systemic scleroderma	4.02e-06	3.31e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL1A—systemic scleroderma	3.98e-06	3.28e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.97e-06	3.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TGFB1—systemic scleroderma	3.97e-06	3.27e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD40LG—systemic scleroderma	3.96e-06	3.26e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CCL2—systemic scleroderma	3.87e-06	3.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—CCL2—systemic scleroderma	3.87e-06	3.18e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL1B—systemic scleroderma	3.84e-06	3.16e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—MMP9—systemic scleroderma	3.81e-06	3.14e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—TGFB1—systemic scleroderma	3.78e-06	3.11e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—NOS3—systemic scleroderma	3.77e-06	3.1e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CCL2—systemic scleroderma	3.73e-06	3.07e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—NOS3—systemic scleroderma	3.72e-06	3.06e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EDN1—systemic scleroderma	3.65e-06	3e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EDN1—systemic scleroderma	3.57e-06	2.94e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—NOS3—systemic scleroderma	3.52e-06	2.9e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EDN1—systemic scleroderma	3.51e-06	2.89e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TGFB1—systemic scleroderma	3.48e-06	2.86e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TGFB1—systemic scleroderma	3.45e-06	2.84e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—NOS3—systemic scleroderma	3.45e-06	2.84e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL1B—systemic scleroderma	3.43e-06	2.82e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CTGF—systemic scleroderma	3.4e-06	2.8e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	3.38e-06	2.79e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EDN1—systemic scleroderma	3.38e-06	2.79e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EDN1—systemic scleroderma	3.34e-06	2.75e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TGFB1—systemic scleroderma	3.34e-06	2.75e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—NOS3—systemic scleroderma	3.32e-06	2.74e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCL2—systemic scleroderma	3.27e-06	2.7e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL1B—systemic scleroderma	3.24e-06	2.67e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CTGF—systemic scleroderma	3.21e-06	2.65e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NOS3—systemic scleroderma	3.17e-06	2.61e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TGFB1—systemic scleroderma	3.14e-06	2.58e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—TGFB1—systemic scleroderma	3.14e-06	2.58e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TGFB1—systemic scleroderma	3.08e-06	2.54e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—NOS3—systemic scleroderma	3.06e-06	2.52e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MMP9—systemic scleroderma	3.02e-06	2.49e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EDN1—systemic scleroderma	2.93e-06	2.41e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL1B—systemic scleroderma	2.92e-06	2.41e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCL2—systemic scleroderma	2.92e-06	2.41e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NOS3—systemic scleroderma	2.92e-06	2.4e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NOS3—systemic scleroderma	2.91e-06	2.39e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL1B—systemic scleroderma	2.86e-06	2.36e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL1B—systemic scleroderma	2.85e-06	2.35e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL1B—systemic scleroderma	2.82e-06	2.32e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCL2—systemic scleroderma	2.77e-06	2.28e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MMP9—systemic scleroderma	2.77e-06	2.28e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL1B—systemic scleroderma	2.71e-06	2.24e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HSPG2—systemic scleroderma	2.7e-06	2.23e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL1B—systemic scleroderma	2.68e-06	2.21e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MMP9—systemic scleroderma	2.67e-06	2.2e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NOS3—systemic scleroderma	2.6e-06	2.15e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EDN1—systemic scleroderma	2.59e-06	2.13e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CTGF—systemic scleroderma	2.57e-06	2.11e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NOS3—systemic scleroderma	2.55e-06	2.1e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TGFB1—systemic scleroderma	2.49e-06	2.05e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCL2—systemic scleroderma	2.49e-06	2.05e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NOS3—systemic scleroderma	2.47e-06	2.03e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—TGFB1—systemic scleroderma	2.46e-06	2.03e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCL2—systemic scleroderma	2.44e-06	2.01e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCL2—systemic scleroderma	2.4e-06	1.98e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL1B—systemic scleroderma	2.35e-06	1.93e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MMP9—systemic scleroderma	2.34e-06	1.93e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—TGFB1—systemic scleroderma	2.33e-06	1.92e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCL2—systemic scleroderma	2.31e-06	1.91e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCL2—systemic scleroderma	2.28e-06	1.88e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TGFB1—systemic scleroderma	2.28e-06	1.88e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—NOS3—systemic scleroderma	2.27e-06	1.87e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NOS3—systemic scleroderma	2.25e-06	1.86e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NOS3—systemic scleroderma	2.22e-06	1.83e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TGFB1—systemic scleroderma	2.2e-06	1.81e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NOS3—systemic scleroderma	2.17e-06	1.79e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NOS3—systemic scleroderma	2.14e-06	1.76e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—TGFB1—systemic scleroderma	2.1e-06	1.73e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MMP9—systemic scleroderma	2.09e-06	1.72e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	2.09e-06	1.72e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL1B—systemic scleroderma	2.08e-06	1.71e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—NOS3—systemic scleroderma	2.07e-06	1.7e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NOS3—systemic scleroderma	2.06e-06	1.7e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CTGF—systemic scleroderma	2.05e-06	1.69e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NOS3—systemic scleroderma	2.04e-06	1.68e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—TGFB1—systemic scleroderma	2.02e-06	1.67e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCL2—systemic scleroderma	2e-06	1.65e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MMP9—systemic scleroderma	1.98e-06	1.63e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TGFB1—systemic scleroderma	1.93e-06	1.59e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—TGFB1—systemic scleroderma	1.92e-06	1.58e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOS3—systemic scleroderma	1.78e-06	1.47e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MMP9—systemic scleroderma	1.78e-06	1.47e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCL2—systemic scleroderma	1.77e-06	1.46e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—systemic scleroderma	1.74e-06	1.44e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TGFB1—systemic scleroderma	1.72e-06	1.42e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—systemic scleroderma	1.72e-06	1.42e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—systemic scleroderma	1.68e-06	1.39e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—systemic scleroderma	1.65e-06	1.36e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—systemic scleroderma	1.63e-06	1.35e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—systemic scleroderma	1.63e-06	1.34e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.58e-06	1.3e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOS3—systemic scleroderma	1.58e-06	1.3e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—systemic scleroderma	1.49e-06	1.23e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NOS3—systemic scleroderma	1.48e-06	1.22e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—systemic scleroderma	1.47e-06	1.21e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—systemic scleroderma	1.44e-06	1.18e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—systemic scleroderma	1.43e-06	1.18e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—systemic scleroderma	1.42e-06	1.17e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NOS3—systemic scleroderma	1.4e-06	1.15e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—systemic scleroderma	1.36e-06	1.12e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—systemic scleroderma	1.35e-06	1.11e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—systemic scleroderma	1.27e-06	1.04e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—systemic scleroderma	1.18e-06	9.71e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NOS3—systemic scleroderma	1.12e-06	9.2e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—systemic scleroderma	1.04e-06	8.6e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NOS3—systemic scleroderma	8.91e-07	7.34e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	6.88e-07	5.67e-06	CbGpPWpGaD
